Nau The primary outcomes were rates of hypertensive disorders of pregnancy, gestational diabetes, preterm birth and cesarean delivery between the two cohorts
PMID 8287691
In March 2024, wegovy, a semaglutide or GLP1, was approved to reduce the risk of stroke, heart attacks and other serious cardiovascular problems in patients who are overweight or obese
9,10 Refined pharmacovigilance monitoring as prescription volume continues to climb, allowing researchers to better separate true drug-driven alopecia from weight-loss-driven telogen effluvium
Dosage and frequency depend on individual patient condition and doctor's recommendation
Patients should report any new or worsening mood changes, unusual anxiety, or agitation to their provider, as these may reflect underlying psychiatric condition changes or medication response rather than drug interaction